Pasteurizable, freeze-driable hemoglobin-based blood substitute
US5364932A · kind A · utility
Assignee
Inventor
Key dates
| Filing date | Jul 27, 1992 |
| Grant date | Nov 15, 1994 |
| Priority date | — |
| Expiry date | Jul 27, 2012 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P7/08
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present specification describes a process by which a blood substitute (hereinafter referred to as "HemoSafe") is derived from uniformly stabilized monomers and polymers of deoxyhemoglobin in its tight (T) conformation, with oxygen affinity similar to that of human blood. Two classes of HemoSafe are derived respectively from anima-hemoglobin and human-hemoglobin. HemoSafe (animal) differs from HemoSafe (human) in that it is free of polymers in order to reduce potential immunogenicity if used in man. Both types of HemoSafe may be derived in the following manner. The stabilized deoxyhemoglobins are converted to their carbonmonoxy derivatives (CO-HemoSafe) which are then stable under pasteurization conditions to render them viral disease transmission-free. CO-HemoSafes are stable for 2 months at 56.degree. C. in either the solution or the freeze-dried state. For transfusion CO-HemoSafes are easily oxygenated under sterile conditions by photoconversion yielding oxy-HemoSafe. In addition a transfusable met-hemoglobin derivative for treatment of cyanide poisoning, is derived by converting oxy-HemoSafe to met-HemoSafe.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.